2012 || Pharmaceuticals || Myocardial Infarction – Pipeline Review, H2 2012 || Aarkstore.com

1. Myocardial Infarction – Pipeline Review, H2 2012
Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Myocardial Infarction – Pipeline Review, H2 2012
RSS link of Global Markets Direct
Summary
Global Markets Direct’s, Myocardial Infarction - Pipeline Review, H2 2012, provides
an overview of the Myocardial Infarction therapeutic pipeline. This report provides
information on the therapeutic development for Myocardial Infarction, complete
with latest updates, and special features on late-stage and discontinued projects. It
also reviews key players involved in the therapeutic development for Myocardial
Infarction. Myocardial Infarction - Pipeline Review, H2 2012 is built using data and
information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Myocardial Infarction.
- A review of the Myocardial Infarction products under development by companies
and universities/research institutes based on information derived from company
and industry-specific sources.
- Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.

2. Myocardial Infarction – Pipeline Review, H2 2012
Table of contents:
List of Tables 5
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Myocardial Infarction Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Myocardial Infarction 11
Myocardial Infarction Therapeutics under Development by Companies 13
Myocardial Infarction Therapeutics under Investigation by Universities/Institutes
18
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Myocardial Infarction Therapeutics – Products under Development by Companies
25
Myocardial Infarction Therapeutics – Products under Investigation by
Universities/Institutes 29
Companies Involved in Myocardial Infarction Therapeutics Development 31
Cardium Therapeutics, Inc. 31
Baxter International Inc. 32
Boehringer Ingelheim GmbH 33
F. Hoffmann-La Roche Ltd. 34
Osiris Therapeutics, Inc. 35
Amgen Inc. 36
Advanced Cell Technology, Inc. 37
Athersys, Inc. 38
GlaxoSmithKline plc 39
ViaCord 40
BioLineRx, Ltd. 41

3. Myocardial Infarction – Pipeline Review, H2 2012
Ark Therapeutics Group plc 42
Merck Serono S.A. 43
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H2 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H2
2012&PubId=&pagenum=1
Myocardial Infarction – Pipeline Review, H2 2012
Metastatic Liver Cancer – Pipeline Review, H2 2012
Mantle Cell Lymphoma – Pipeline Review, H2 2012
Malignant Mesothelioma – Pipeline Review, H2 2012
Rectal Cancer – Pipeline Review, H2 2012
Chemotherapy Effects – Pipeline Review, H2 2012
Follicular Lymphoma – Pipeline Review, H2 2012
Sleep Disorders – Pipeline Review, H2 2012
Neuroblastoma – Pipeline Review, H2 2012

4. Myocardial Infarction – Pipeline Review, H2 2012
Cytomegalovirus (HHV-5) Infections – Pipeline Review, H2 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com